Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Cardiol Therapeutics, with a price target of $8.00. T...

Canaccord Genuity Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)

Cardiol Therapeutics Inc. ( ($CRDL) ) has released its Q3 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to i...

Current Quarter	$-0.09	Next Quarter	$-0.07
Current Year	$-0.35	Next Year	$-0.35
QoQ Growth	+22.2%	YoY Growth	+0.0%
3Y EPS CAGR	+11.3%	Target Price	$6.74
Consensus	Buy	Upside	+524.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$1.08	-0.92%	352.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$1.08	-0.9%	352.10K
3
4
5
6

CRDL

CRDL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel